1. Home
  2. GPI vs ACAD Comparison

GPI vs ACAD Comparison

Compare GPI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Group 1 Automotive Inc.

GPI

Group 1 Automotive Inc.

HOLD

Current Price

$350.87

Market Cap

4.0B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.80

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPI
ACAD
Founded
1995
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
3.8B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
GPI
ACAD
Price
$350.87
$21.80
Analyst Decision
Strong Buy
Buy
Analyst Count
7
22
Target Price
$447.14
$30.55
AVG Volume (30 Days)
108.5K
1.3M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
0.57%
N/A
EPS Growth
N/A
69.12
EPS
10.85
2.30
Revenue
$11,123,721,000.00
$726,437,000.00
Revenue This Year
$3.41
$18.80
Revenue Next Year
$3.10
$11.70
P/E Ratio
$14.28
$9.80
Revenue Growth
2.17
40.45
52 Week Low
$292.44
$14.45
52 Week High
$488.39
$28.35

Technical Indicators

Market Signals
Indicator
GPI
ACAD
Relative Strength Index (RSI) 61.05 47.72
Support Level $318.25 $21.51
Resistance Level $409.75 $22.03
Average True Range (ATR) 13.85 0.61
MACD 1.08 0.04
Stochastic Oscillator 53.60 42.51

Price Performance

Historical Comparison
GPI
ACAD

About GPI Group 1 Automotive Inc.

Group 1 owns and operates 32 collision centers and 254 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 109 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: